Headlines about Heska (NASDAQ:HSKA) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heska earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.8703716835088 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern’s analysis:
- Heska (HSKA) Upgraded to Buy by BidaskClub (americanbankingnews.com)
- $31.65 Million in Sales Expected for Heska Co. (HSKA) This Quarter (americanbankingnews.com)
- Heska Co. (HSKA) Expected to Announce Earnings of $0.40 Per Share (americanbankingnews.com)
- Comparing Heska (HSKA) and The Competition (americanbankingnews.com)
HSKA has been the subject of a number of analyst reports. B. Riley decreased their price target on Heska from $93.00 to $77.00 and set a “neutral” rating for the company in a research note on Thursday, March 1st. BidaskClub upgraded Heska from a “sell” rating to a “hold” rating in a research note on Friday, March 16th. Canaccord Genuity restated a “buy” rating and issued a $95.00 price target on shares of Heska in a research note on Thursday, March 1st. TheStreet downgraded Heska from a “b-” rating to a “c+” rating in a research note on Friday, March 9th. Finally, ValuEngine downgraded Heska from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $104.08.
HSKA stock traded up $1.01 during mid-day trading on Friday, reaching $83.17. The company had a trading volume of 44,767 shares, compared to its average volume of 56,668. The company has a market cap of $617.75, a price-to-earnings ratio of 40.18, a P/E/G ratio of 2.31 and a beta of 0.65. Heska has a 52 week low of $56.59 and a 52 week high of $115.00.
Heska (NASDAQ:HSKA) last issued its earnings results on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.07. Heska had a return on equity of 16.23% and a net margin of 7.53%. The company had revenue of $36.04 million during the quarter, compared to the consensus estimate of $40.56 million. During the same period in the previous year, the company posted $0.46 EPS. The firm’s revenue for the quarter was down 8.8% compared to the same quarter last year. equities analysts forecast that Heska will post 1.95 EPS for the current fiscal year.
WARNING: “Heska (HSKA) Earning Somewhat Positive Media Coverage, Report Shows” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2018/04/22/heska-hska-earning-somewhat-positive-media-coverage-report-shows.html.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.